Comparative Analysis of New Drugs Approved by the United States and China in 2023

Ma Qiaoning, Zheng Yang, Yuan Yanfang, Wang Wenya

Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (11) : 1235-1246.

PDF(1251 KB)
PDF(1251 KB)
Chinese Pharmaceutical Affairs ›› 2024, Vol. 38 ›› Issue (11) : 1235-1246. DOI: 10.16153/j.1002-7777.20240547
Supervision & Administration

Comparative Analysis of New Drugs Approved by the United States and China in 2023

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 38(11): 1235-1246 https://doi.org/10.16153/j.1002-7777.20240547

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1251 KB)

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-4
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉